Industries > Pharma > Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast to 2029

Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast to 2029

Antifibrotics, Tyrosine Kinase Inhibitors, Anti-inflammatory Drugs, Immunosuppressants, Other MoA, Innovator Drugs

PUBLISHED: 26 November 2019
PAGES: 171
PRODUCT CODE: PHA0599
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0599 Categories: , Tags: ,

The global anti-idiopathic pulmonary fibrosis drugs market is expected to grow at a CAGR of 16.7% in the first half of the forecast period. In 2018, the anti-fibrotics held the largest market share (51%) followed by the tyrosine kinase inhibitors.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 171-page report you will receive 69 tables and 97 figures– all unavailable elsewhere.

The 171-page report provides clear detailed insight into the global anti-idiopathic pulmonary fibrosis drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Anti-Idiopathic Pulmonary Fibrosis Drugs market forecasts to 2029

• This report also breaks down the revenue forecast for the global anti-idiopathic pulmonary fibrosis drugs market by mechanism of action:
• Antifibrotics
• Tyrosine Kinase Inhibitors
• Anti-inflammatory Drugs
• Immunosuppressants
• Other MoA

Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast to 2029

• This report also breaks down the revenue forecast for the global anti-idiopathic pulmonary fibrosis drugs market by Innovator and Off-label drugs:
• Innovator Drugs
• Off-label Drugs

• This report provides individual revenue forecasts to 2029 for these national markets:
• US
• Japan
• EU5: Germany, France, the UK, Italy, Spain
• Rest of World

• This report provides individual revenue forecasts to 2029 for these marketed drugs:
• Esbriet
• Ofev

• Our study gives qualitative analysis of the anti-idiopathic pulmonary fibrosis drugs market. It discusses:
• Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in the G7 markets
• Epidemiology of Idiopathic Pulmonary Fibrosis by disease severity
• Epidemiology of Idiopathic Pulmonary Fibrosis by gender
• Discussion on novel clinical molecules under development for the treatment of Idiopathic Pulmonary Fibrosis
Pricing and Reimbursement Overview on Ofev and Esbriet (by NICE, SMC, PBAC, CADTH, G-BA, HAS)
A SWOT Analysis on the anti-idiopathic pulmonary fibrosis drugs market

• Our study discusses the marketed anti-idiopathic pulmonary fibrosis drugs and pipeline anti-idiopathic pulmonary fibrosis drugs from these companies:
• Actelion
• Afferent Pharmaceuticals
• Asahi Kasei Pharma
• Bellerophon Therapeutics
• Biogen
• Boehringer Ingelheim
• FibroGen
• Galapagos
• Galecto Biotech
• Genentech
• Global Blood Therapeutics
• GSK
• Kadmon Pharmaceuticals
• LTT Bio-Pharma
• MediciNova
• Merck
• Moerae
• Pacific Therapeutics
• Promedior
• ProMetic Life Sciences
• Roche
• Sanofi
• Teva
• Zai Lab

Visiongain’s study is intended for anyone requiring commercial analyses for the global Anti-Idiopathic Pulmonary Fibrosis Drugs Market. You find data, trends and predictions.

Buy our report today Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Trends : Antifibrotics, Tyrosine Kinase Inhibitors, Anti-inflammatory Drugs, Immunosuppressants, Other MoA, Innovator Drugs.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast to 2029


Download sample pages

Complete the form below to download your free sample pages for Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast to 2029


Latest Pharma news

Visiongain Publishes Dermatological Drugs Market Report 2021-2031

The global market for dermatological drugs is ascending and has made significant gains in skin treatments. The players in the dermatological drugs market are striving to tap the opportunities that this market offers.

18 January 2021

READ

Visiongain Publishes Antigen Skin Test Market Report to 2031

The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market. Increasing health concerns among population and growing incidences of fungal & bacterial infection are some of the factors driving the growth of Antigen Skin Test market.

12 January 2021

READ

Visiongain Publishes Anti-Infective Vaccines Market Report Report to 2031

The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market.

11 January 2021

READ

Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031

Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.

08 January 2021

READ

Categories

Category